

**Clinical Policy: Secukinumab (Cosentyx)**

Reference Number: CP.PHAR.261

Effective Date: 08.16

Last Review Date: 02.24

Line of Business: Medicaid

[Coding Implications](#)[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Description**

Secukinumab (Cosentyx<sup>®</sup>) is an interleukin-17A (IL-17A) antagonist.

**FDA Approved Indication(s)**

Cosentyx is indicated for the treatment of:

- Moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy
- Active psoriatic arthritis (PsA) in patients 2 years of age and older
- Adults with active ankylosing spondylitis (AS)
- Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation
- Active enthesitis-related arthritis (ERA) in patients 4 years of age and older
- Adults with moderate to severe hidradenitis suppurativa (HS)

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Cosentyx is **medically necessary** when the following criteria are met:

**I. Initial Approval Criteria****A. Axial Spondyloarthritis (must meet all):**

1. Diagnosis of AS or nr-axSpA;
2. Prescribed by or in consultation with a rheumatologist;
3. Age  $\geq$  18 years;
4. Failure of at least TWO non-steroidal anti-inflammatory drugs (NSAIDs) at up to maximally indicated doses, each used for  $\geq$  4 weeks unless clinically significant adverse effects are experienced or all are contraindicated;
5. For AS, member meets ALL\* of the following, each used for  $\geq$  3 consecutive months, unless clinically significant adverse effects are experienced or all are contraindicated (a, b, and c, *see Appendix D*):
  - a. Failure of one adalimumab product (e.g., *Hadlima*<sup>™</sup>, *Yusimry*<sup>™</sup>, *adalimumab-adaz*, *adalimumab-adbm*, and *adalimumab-fkjp* are preferred), unless the member has had a history of failure of two TNF blockers;
  - b. Failure of Taltz<sup>®</sup>;

- c. If member has not responded or is intolerant to one or more TNF blockers, Xeljanz<sup>®</sup>/Xeljanz XR<sup>®</sup>, unless member has cardiovascular risk and benefits do not outweigh the risk of treatment;  
*\*Prior authorization may be required for adalimumab products, Xeljanz/Xeljanz XR, and Taltz*
6. For nr-axSpA: Failure of Taltz\*, used for  $\geq 3$  consecutive months, unless contraindicated or clinically significant adverse effects are experienced;  
*\*Prior authorization may be required for Taltz*
7. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (*see Section III: Diagnoses/Indications for which coverage is NOT authorized*);
8. Dose does not exceed one of the following (a or b):
  - a. SC: 150 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 150 mg every 4 weeks;
  - b. IV: 6 mg/kg at week 0, followed by maintenance dose 1.75 mg/kg every 4 weeks.

**Approval duration: 6 months**

**B. Enthesitis-related Arthritis (must meet all):**

1. Diagnosis of ERA;
2. Prescribed by or in consultation with a rheumatologist;
3. Age  $\geq 4$  years and  $< 18$  years;
4. Failure of at least TWO non-steroidal anti-inflammatory drugs (NSAIDs) at up to maximally indicated doses, each used for  $\geq 4$  weeks unless clinically significant adverse effects are experienced or all are contraindicated;
5. Member meets one of the following (a or b):
  - a. Failure of a  $\geq 3$  consecutive month trial of MTX at up to maximally indicated doses;
  - b. Member has intolerance or contraindication to MTX (*see Appendix D*), and failure of a  $\geq 3$  consecutive month trial of at least ONE conventional disease-modifying anti-rheumatic drug (e.g., sulfasalazine, leflunomide) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
6. If disease is polyarticular ( $\geq 5$  joints ever involved), failure of Actemra<sup>®</sup>, used for  $\geq 3$  consecutive months, unless clinically significant adverse effects are experienced or both are contraindicated;
7. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (*see Section III: Diagnoses/Indications for which coverage is NOT authorized*);
8. Dose does not exceed one of the following (a or b):
  - a. Weight  $> 15$  kg and  $< 50$  kg: 75 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 75 mg every 4 weeks;
  - b. Weight  $\geq 50$  kg: 150 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 150 mg every 4 weeks.

**Approval duration: 6 months**

**C. Plaque Psoriasis (must meet all):**

1. Diagnosis of moderate-to-severe PsO as evidenced by involvement of one of the following (a or b):

- a.  $\geq 3\%$  of total body surface area;
- b. Hands, feet, scalp, face, or genital area;
2. Prescribed by or in consultation with a dermatologist or rheumatologist;
3. Age  $\geq 6$  years;
4. Member meets one of the following (a, b, or c):
  - a. Failure of a  $\geq 3$  consecutive month trial of methotrexate (MTX) at up to maximally indicated doses;
  - b. Member has intolerance or contraindication to MTX (*see Appendix D*), and failure of a  $\geq 3$  consecutive month trial of cyclosporine or acitretin at up to maximally indicated doses, unless clinically significant adverse effects are experienced or both are contraindicated;
  - c. Member has intolerance or contraindication to MTX, cyclosporine, and acitretin, and failure of phototherapy, unless contraindicated or clinically significant adverse effects are experienced;
5. For age  $\geq 18$  years, member meets ONE of the following, unless contraindicated or clinically significant adverse effects are experienced (a or b, *see Appendix D*):
  - a. Failure of a  $\geq 3$  consecutive month trial of one\* adalimumab product (e.g., *Hadlima, Yusimry, adalimumab-adaz, adalimumab-adbm, and adalimumab-fkjp are preferred*);
  - b. History of failure of two TNF blockers;  
*\*Prior authorization may be required for adalimumab products*
6. Failure of a  $\geq 3$  consecutive month trial of Taltz\*, unless contraindicated or clinically significant adverse effects are experienced;  
*\*Prior authorization may be required for Taltz*
7. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (*see Section III: Diagnoses/Indications for which coverage is NOT authorized*);
8. Dose does not exceed the following:
  - a. Age  $\geq 18$  years: 300 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 300 mg every 4 weeks;
  - b. Age 6 to 17 years and weight  $< 50$  kg: 75 mg at weeks 0, 1, 2, 3 and 4, followed by maintenance dose of 75 mg every 4 weeks;
  - c. Age 6 to 17 years and weight  $\geq 50$  kg: 150 mg at weeks 0, 1, 2, 3 and 4, followed by maintenance dose of 150 mg every 4 weeks.

**Approval duration: 6 months**

**D. Psoriatic Arthritis (must meet all):**

1. Diagnosis of PsA;
2. Prescribed by or in consultation with a dermatologist or rheumatologist;
3. Age  $\geq 2$  years;
4. For members  $\geq 18$  years, failure of ALL\* of the following, each used for  $\geq 3$  consecutive months, unless clinically significant adverse effects are experienced or all are contraindicated (a, b, c, and d, *see Appendix D*):
  - a. Failure of one adalimumab product (e.g., *Hadlima, Yusimry, adalimumab-adaz, adalimumab-adbm, and adalimumab-fkjp are preferred*), unless the member has had a history of failure of two TNF blockers;
  - b. Otezla<sup>®</sup>;

- c. Taltz;
- d. If member has not responded or is intolerant to one or more TNF blockers, Xeljanz/Xeljanz XR, unless member has cardiovascular risk and benefits do not outweigh the risk of treatment;  
*\*Prior authorization may be required for adalimumab products, Otezla, Taltz, and Xeljanz/Xeljanz XR*
5. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (*see Section III: Diagnoses/Indications for which coverage is NOT authorized*);
6. Dose does not exceed one of the following (a or b):
  - a. PsA alone (i or ii):
    - i. Adults (1 or 2):
      - 1) SC: 150 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 150 mg every 4 weeks;
      - 2) IV: 6 mg/kg at week 0, followed by maintenance dose 1.75 mg/kg every 4 weeks;
    - ii. Pediatric (1 or 2):
      - 1) Weight > 15 kg and < 50 kg, SC: 75 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 75 mg every 4 weeks;
      - 2) Weight ≥ 50 kg, SC: 150 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 150 mg every 4 weeks;
  - b. PsA with PsO and ≥ 18 years: 300 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 300 mg every 4 weeks.

**Approval duration: 6 months**

**E. Hidradenitis Suppurativa (must meet all):**

1. Diagnosis of HS;
2. Prescribed by or in consultation with a dermatologist, rheumatologist, or gastroenterologist;
3. Age ≥ 18 years;
4. Documentation of Hurley stage II or stage III (*see Appendix D*);
5. Failure of one adalimumab product\* (e.g., *Hadlima<sup>™</sup>*, *Yusimry<sup>™</sup>*, *adalimumab-adaz*, *adalimumab-adbm*, and *adalimumab-fkjp* are preferred), unless the member has had a history of failure of two TNF blockers;  
*\*Prior authorization may be required for adalimumab products*
6. Failure of at least TWO of the following, each tried for ≥ 3 consecutive months from different therapeutic classes, at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated:
  - a. Systemic antibiotic therapy (e.g., clindamycin, minocycline, doxycycline, rifampin);
  - b. Oral retinoids (e.g., acitretin, isotretinoin);
  - c. Hormonal treatment (e.g., estrogen-containing combined oral contraceptives, spironolactone);
7. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (*see Section III: Diagnoses/Indications for which coverage is NOT authorized*);
8. Dose does not exceed 300 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 300 mg every 4 weeks.

**Approval duration: 6 months**

**F. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. All Indications in Section I (must meet all):**

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member meets one of the following (a or b):
  - a. For HS: At least a 25% reduction in inflammatory nodules and abscesses;
  - b. For all other indications: Member is responding positively to therapy;
3. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (*see Section III: Diagnoses/Indications for which coverage is NOT authorized*);
4. If request is for a dose increase, new dose does not exceed one of the following (a, b, c, d, or e):
  - a. PsO alone (i, ii, or iii):
    - i. Age  $\geq$  18 years: 300 mg every 4 weeks;
    - ii. Age 6 to 17 years and weight  $<$  50 kg: 75 mg every 4 weeks;
    - iii. Age 6 to 17 years and weight  $\geq$  50 kg: 150 mg every 4 weeks;
  - b. PsA (i or ii):
    - i. Adults (a, b, or c):
      - a) IV: 1.75 mg/kg every 4 weeks;
      - b) SC: 150 mg every 4 weeks;
      - c) SC: 300 mg every 4 weeks, if documentation supports inadequate response to a  $\geq$  3 consecutive month trial of 150 mg every 4 weeks or member has coexistent PsO;

- ii. Pediatric (a or b):
  - a) Weight > 15 kg and < 50 kg, SC: 75 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 75 mg every 4 weeks;
  - b) Weight ≥ 50 kg, SC: 150 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 150 mg every 4 weeks;
- c. AS, nr-axSpA (i, ii, or iii):
  - i. IV: 1.75 mg/kg every 4 weeks;
  - ii. SC: 150 mg every 4 weeks;
  - iii. SC: For AS only: 300 mg every 4 weeks, if documentation supports inadequate response to a ≥ 3 consecutive month trial of 150 mg every 4 weeks;
- d. ERA (i or ii):
  - i. Weight > 15 kg and < 50 kg: 75 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 75 mg every 4 weeks;
  - ii. Weight ≥ 50 kg: 150 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 150 mg every 4 weeks;
- e. HS (i or ii):
  - i. 300 mg every 4 weeks;
  - ii. 300 mg every 2 weeks, if documentation supports inadequate response to 300 mg every 4 weeks.

**Approval duration: 12 months (If new dosing regimen, approve for 6 months)**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents;
- B. Combination use with biological disease-modifying antirheumatic drugs (bDMARDs) or potent immunosuppressants, including but not limited to any tumor necrosis factor (TNF) antagonists [e.g., Cimzia<sup>®</sup>, Enbrel<sup>®</sup>, Humira<sup>®</sup> and its biosimilars, Simponi<sup>®</sup>, Avsola<sup>™</sup>, Inflectra<sup>™</sup>, Remicade<sup>®</sup>, Renflexis<sup>™</sup>], interleukin agents [e.g., Arcalyst<sup>®</sup> (IL-1 blocker), Ilaris<sup>®</sup> (IL-1 blocker), Kineret<sup>®</sup> (IL-1RA), Actemra<sup>®</sup> (IL-6RA), Tofidence<sup>™</sup> (IL-6RA),

Kevzara<sup>®</sup> (IL-6RA), Stelara<sup>®</sup> (IL-12/23 inhibitor), Wezlana<sup>™</sup> (IL-12/23 inhibitor), Cosentyx<sup>®</sup> (IL-17A inhibitor), Taltz<sup>®</sup> (IL-17A inhibitor), Siliq<sup>™</sup> (IL-17RA), Ilumya<sup>™</sup> (IL-23 inhibitor), Skyrizi<sup>™</sup> (IL-23 inhibitor), Tremfya<sup>®</sup> (IL-23 inhibitor), Janus kinase inhibitors (JAKi) [e.g., Xeljanz<sup>®</sup>/Xeljanz<sup>®</sup> XR, Cibinqo<sup>™</sup>, Olumiant<sup>™</sup>, Rinvoq<sup>™</sup>], anti-CD20 monoclonal antibodies [Rituxan<sup>®</sup>, Riabni<sup>™</sup>, Ruxience<sup>™</sup>, Truxima<sup>®</sup>, Rituxan Hycela<sup>®</sup>], selective co-stimulation modulators [Orencia<sup>®</sup>], and integrin receptor antagonists [Entyvio<sup>®</sup>] because of the additive immunosuppression, increased risk of neutropenia, as well as increased risk of serious infections.

#### IV. Appendices/General Information

##### *Appendix A: Abbreviation/Acronym Key*

AS: ankylosing spondylitis

ERA: enthesitis-related arthritis

FDA: Food and Drug Administration

HS: Hidradenitis suppurativa

IL-17A: interleukin-17A

ILAR: International League of  
Associations for Rheumatology

JAKi: Janus kinase inhibitors

MTX: methotrexate

nr-axSpA: non-radiographic axial  
spondyloarthritis

NSAID: non-steroidal anti-inflammatory  
drug

PsA: psoriatic arthritis

PsO: plaque psoriasis

##### *Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

<b>Drug Name</b>	<b>Dosing Regimen</b>	<b>Dose Limit/ Maximum Dose</b>
acitretin (Soriatane <sup>®</sup> )	<b>PsO</b> 25 or 50 mg PO QD	50 mg/day
cyclosporine (Sandimmune <sup>®</sup> , Neoral <sup>®</sup> )	<b>PsO</b> 2.5 – 4 mg/kg/day PO divided BID	4 mg/kg/day
clindamycin (Cleocin <sup>®</sup> ) + rifampin (Rifadin <sup>®</sup> )	<b>HS*</b> clindamycin 300 mg PO BID and rifampin 300 mg PO BID	clindamycin: 600 mg/day rifampin: 600 mg/day
doxycycline (Acticlate <sup>®</sup> )	<b>HS*</b> 50 – 100 mg PO BID	300 mg/day
Hormonal agents (e.g., estrogen-containing combined oral contraceptives, spironolactone)	<b>HS</b> varies	varies
Isotretinoin (Absorica <sup>®</sup> , Amnesteem <sup>®</sup> ,	<b>HS</b> varies	varies

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Claravis <sup>®</sup> , Myorisan <sup>®</sup> , Zenatane <sup>®</sup> )		
leflunomide (Arava <sup>®</sup> )	<b>ERA</b> Weight < 20 kg: 10 mg every other day Weight 20 - 40 kg: 10 mg/day Weight > 40 kg: 20 mg/day	20 mg/day
methotrexate (Rheumatrex <sup>®</sup> )	<b>PsO</b> 10 to 25 mg/week IM, SC or PO or 2.5 mg PO Q12 hr for 3 doses/week  <b>ERA</b> 10 – 25 mg/week PO or 2.5 mg PO Q12 hr for 3 doses/week	30 mg/week
minocycline (Minocin <sup>®</sup> )	<b>HS*</b> 50 – 100 mg PO BID	200 mg/day
sulfasalazine (Azulfidine <sup>®</sup> )	<b>ERA</b> 30 to 50 mg/kg/day PO, given in 2 divided doses	2 g/day
NSAIDs (e.g., indomethacin, ibuprofen, naproxen, celecoxib)	<b>AS, nr-axSpA, ERA</b> Varies	Varies
Actemra <sup>®</sup> (tocilizumab)	<b>PJIA (includes ERA with polyarticular disease)</b> • Weight < 30 kg: 10 mg/kg IV every 4 weeks or 162 mg SC every 3 weeks • Weight ≥ 30 kg: 8 mg/kg IV every 4 weeks or 162 mg SC every 2 weeks <i>See Appendix E for dose rounding guidelines</i>	IV: 10 mg/kg every 4 weeks  SC: 162 mg every 2 weeks
Cimzia <sup>®</sup> (certolizumab)	<b>nr-axSpA</b> <u>Initial dose:</u> 400 mg SC at 0, 2, and 4 weeks <u>Maintenance dose:</u> 200 mg SC every other week (or 400 mg SC every 4 weeks)	400 mg every 4 weeks
Hadlima (adalimumab-bwwd), Yusimry (adalimumab-aqvh), adalimumab-adaz (Hyrimoz <sup>®</sup> ), adalimumab-fkjp	<b>AS</b> 40 mg SC every other week  <b>PsA</b> 40 mg SC every other week  <b>PsO</b>	<b>AS, PsA, PsO:</b> 40 mg every other week  <b>HS:</b> 40 mg/week



Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
(Hulio <sup>®</sup> ), adalimumab-adbm (Cyltezo <sup>®</sup> )	<p><u>Initial dose:</u> 80 mg SC</p> <p><u>Maintenance dose:</u> 40 mg SC every other week starting one week after initial dose</p> <p><b>HS</b> <u>Initial dose:</u> 160 mg SC on day 1, then 80 mg SC on Day 15</p> <p><u>Maintenance dose:</u> 40 mg SC every week or 80 mg SC every other week starting on Day 29</p>	
Otezla <sup>®</sup> (apremilast)	<p><b>PsA</b> <u>Initial dose:</u> Day 1: 10 mg PO QAM Day 2: 10 mg PO QAM and 10 mg PO QPM Day 3: 10 mg PO QAM and 20 mg PO QPM Day 4: 20 mg PO QAM and 20 mg PO QPM Day 5: 20 mg PO QAM and 30 mg PO QPM</p> <p><u>Maintenance dose:</u> Day 6 and thereafter: 30 mg PO BID</p>	60 mg/day
Taltz <sup>®</sup> (ixekizumab)	<p><b>AS, nr-axSpA, PsA</b> <u>Initial dose:</u> 160 mg (two 80 mg injections) SC at week 0 <u>Maintenance dose:</u> 80 mg SC every 4 weeks</p> <p><b>PsO</b> <u>Initial dose:</u> 160 mg (two 80 mg injections) SC at week 0, then 80 mg SC at weeks 2, 4, 6, 8, 10, and 12 <u>Maintenance dose:</u> 80 mg SC every 4 weeks</p>	80 mg every 4 weeks
Xeljanz <sup>®</sup>	<b>AS, PsA</b>	10 mg/day

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
(tofacitinib)	5 mg PO BID	
Xeljanz XR <sup>®</sup> (tofacitinib extended-release)	<b>AS, PsA</b> 11 mg PO QD	11 mg/day

Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.

\*Off-label

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): serious hypersensitivity reaction to secukinumab or to any of the excipients
- Boxed warning(s): none reported

*Appendix D: General Information*

- Definition of failure of MTX or DMARDs
  - Child-bearing age is not considered a contraindication for use of MTX. Each drug has risks in pregnancy. An educated patient and family planning would allow use of MTX in patients who have no intention of immediate pregnancy.
  - Social use of alcohol is not considered a contraindication for use of MTX. MTX may only be contraindicated if patients choose to drink over 14 units of alcohol per week. However, excessive alcohol drinking can lead to worsening of the condition, so patients who are serious about clinical response to therapy should refrain from excessive alcohol consumption.
- Examples of positive response to therapy may include, but are not limited to:
  - Reduction in joint pain/swelling/tenderness
  - Improvement in ESR/CRP levels
  - Improvements in activities of daily living
- PsA: According to the 2018 American College of Rheumatology and National Psoriasis Foundation guidelines, TNF inhibitors or oral small molecules (e.g., methotrexate, sulfasalazine, cyclosporine, leflunomide, apremilast) are preferred over other biologics (e.g., interleukin-17 inhibitors or interleukin-12/23 inhibitors) for treatment-naïve disease. TNF inhibitors are also generally recommended over oral small molecules as first-line therapy unless disease is not severe, member prefers oral agents, or TNF inhibitor therapy is contraindicated.
- ERA: Current International League of Associations for Rheumatology (ILAR) classification criteria divide JIA into 7 mutually exclusive categories defined by the number of joints involved, presence or absence of extraarticular manifestations, and presence or absence of additional markers including rheumatoid factor (RF) and HLA-B27. While the current ILAR classification criteria have been useful for identifying homogeneous groups of patients for research, more recent data suggest that these categories may not entirely reflect the underlying genetic and clinical heterogeneity of the disease or be relevant for guiding treatment decisions. According to the 2019 American College of Rheumatology, current treatment guideline focuses treatment approaches based on broad clinical phenotypes rather than ILAR categories.

- AS and nr-axSpA: Although the 2019 ACR guidelines for AS recommend the use of TNF inhibitors over IL-17A antagonists such as Taltz or Cosentyx, this recommendation was based on “greater experience with TNF inhibitors and familiarity with their long-term safety and toxicity” rather than differences in efficacy.
- TNF blockers:
  - Etanercept (Enbrel<sup>®</sup>), adalimumab (Humira<sup>®</sup>) and its biosimilars, infliximab (Remicade<sup>®</sup>) and its biosimilars (Avsola<sup>™</sup>, Renflexis<sup>™</sup>, Inflectra<sup>®</sup>), certolizumab pegol (Cimzia<sup>®</sup>), and golimumab (Simponi<sup>®</sup>, Simponi Aria<sup>®</sup>).
- Hidradenitis suppurativa:
  - HS is sometimes referred to as: "acne inversa, acne conglobata, apocrine acne, apocrinitis, Fox-den disease, hidradenitis axillaris, HS, pyodermia sinifica fistulans, Velpeau’s disease, and Verneuil’s disease."
  - In HS, Hurley stages are used to determine severity of disease. Hurley stage II indicates moderate disease, and is characterized by recurrent abscesses, with sinus tracts and scarring, presenting as single or multiple widely separated lesions. Hurley stage III indicates severe disease, and is characterized by diffuse or near-diffuse involvement presenting as multiple interconnected tracts and abscesses across an entire area.

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
PsO (with or without PsA)	<p>Adults: 300 mg SC at weeks 0, 1, 2, 3, and 4, followed by 300 mg SC every 4 weeks. (for some patients, a dose of 150 mg may be acceptable)</p> <p>Pediatric patients age 6 to 17 years and weight &lt; 50 kg (PsO only): 75 mg SC at weeks 0, 1, 2, 3 and 4, followed by maintenance dose of 75 mg every 4 weeks</p> <p>Pediatric patients age 6 to 17 years and weight ≥ 50 kg (PsO only): 150 mg SC at weeks 0, 1, 2, 3 and 4, followed by maintenance dose of 150 mg every 4 weeks</p>	<p>Adults: 300 mg every 4 weeks</p> <p>Pediatric patients: 150 mg every 4 weeks</p>
PsA	<p><u>Adults:</u></p> <p><i>Subcutaneous:</i></p> <ul style="list-style-type: none"> <li>• With loading dose: 150 mg SC at week 0, 1, 2, 3, and 4, followed by 150 mg SC every 4 weeks</li> <li>• Without loading dose: 150 mg SC every 4 weeks.</li> <li>• If a patient continues to have active psoriatic arthritis, consider a dosage of 300 mg.</li> </ul> <p><i>Intravenous infusion:</i></p> <ul style="list-style-type: none"> <li>• With loading dose: 6 mg/kg IV at week 0, followed by 1.75 mg/kg IV every 4 weeks.</li> <li>• Without loading dose: 1.75 mg/kg IV every 4 weeks.</li> </ul>	<p>Adults: 300 mg every 4 weeks</p> <p>Pediatric patients: 150 mg every 4 weeks</p>

Indication	Dosing Regimen	Maximum Dose
	<p><u>Pediatric:</u> <i>Subcutaneous:</i> Pediatric patients age 2 to 17 years and weight <math>\geq</math> 15 kg and <math>&lt;</math> 50 kg: 75 mg SC at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 75 mg every 4 weeks.</p> <p>Pediatric patients age 2 to 17 years old and weight <math>\geq</math> 50 kg: 150 mg SC at weeks 0, 1, 2, 3, and 4, followed by a maintenance dose of 150 mg every 4 weeks.</p>	
AS, nr-axSpA	<p><i>Subcutaneous:</i></p> <ul style="list-style-type: none"> <li>• With loading dose: 150 mg SC at weeks 0, 1, 2, 3, and 4, followed by 150 mg SC every 4 weeks thereafter.</li> <li>• Without loading dose: 150 mg SC every 4 weeks.</li> <li>• For AS only: if a patient continues to have active ankylosing spondylitis, consider a dosage of 300 mg.</li> </ul> <p><i>Intravenous infusion:</i></p> <ul style="list-style-type: none"> <li>• With loading dose: 6 mg/kg IV at week 0, followed by 1.75 mg/kg IV every 4 weeks.</li> <li>• Without loading dose: 1.75 mg/kg IV every 4 weeks.</li> </ul>	<p>300 mg every 4 weeks</p> <p><u>nr-axSpA (SC):</u> 150 mg every 4 weeks (after loading doses)</p>
ERA	<ul style="list-style-type: none"> <li>• Weight <math>&gt;</math> 15 kg and <math>&lt;</math> 50 kg: 75 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 75 mg every 4 weeks</li> <li>• Weight <math>\geq</math> 50 kg: 150 mg at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 150 mg every 4 weeks</li> </ul>	<p>Weight <math>&lt;</math> 50 kg: 75 mg every 4 weeks (after loading doses)</p> <p>Weight <math>\geq</math> 50 kg: 150 mg every 4 weeks (after loading doses)</p>
HS	<p>300 mg SC at weeks 0, 1, 2, 3, and 4, followed by maintenance dose of 300 mg every 4 weeks</p> <p>Consider increasing the dosage to 300 mg every 2 weeks if patient does not adequately respond</p>	<p>300 mg every 2 weeks</p>

**VI. Product Availability**

- Single-dose UnoReady pen: 300 mg/2 mL
- Single-dose Sensoready<sup>®</sup> pen: 150 mg/mL
- Single-dose prefilled syringe: 75 mg/0.5 mL, 150 mg/mL, 300 mg/2 mL
- Single-dose vial (for IV infusion): 125 mg/5 mL

## VII. References

1. Cosentyx Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2023. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/125504s066,761349s004lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s066,761349s004lbl.pdf). Accessed January 4, 2024.
2. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis & Rheumatology*. 2019. Doi: 10.1002/art.41042.
3. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. *Arthritis Care and Research*. 2019;71(6):717-734. DOI 10.1002/acr.23870.
4. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80:1029-72. Doi:10.1016/j.aad.201811.057.
5. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Ann Rheum Dis*. 2020;79:700–712. Doi:10.1136/annrheumdis-2020-217159.
6. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. *American College of Rheumatology*. 2019; 71(1):5-32. Doi: 10.1002/art.40726.
7. Clinical Pharmacology [database online]. Philadelphia, PA: Elsevier; 2024. Available at: <http://www.clinicalkey.com/pharmacology/>. Accessed January 4, 2024.
8. Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. *J Eur Acad Dermatol Venereol*. April 2015; 29(4):619-44. Epub 2015 Jan 30.
9. Gulliver W, Zouboulis CC, Prens E, et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. *Rev Endocr Metab Disord*. February 1, 2016. Doi: 10.1007/s11154-016-9328-5.
10. Zouboulis, CC. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa. *Expert Review of Clinical Immunology*. August 29, 2016. Doi: 10.1080/1744666X.2016.1221762.
11. Alikhan A, Sayed C, Alavi A, et al. North American Clinical Management Guidelines for Hidradenitis Suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part II: topical, intralesional, and systemic medical management. *J Am Acad Dermatol*. 2019; pii: S0190-9622(19)30368-8. Doi: 10.1016/j.jaad.2019.02.068.
12. Hendricks A, J, Hsiao J, L, Lowes M, A, Shi V, Y: A Comparison of International Management Guidelines for Hidradenitis Suppurativa. *Dermatology* 2021;237:81-96. doi: 10.1159/000503605.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
C9166	Injection, secukinumab, intravenous, 1 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2019 annual review: removed trial and failure of conventional DMARDs (e.g., MTX)/NSAIDs for PsA per 2018 ACR/NPF guidelines; revised approval duration to 6 months if request is for continuation of therapy with a new (e.g., increased dose/frequency) regimen; references reviewed and updated.	03.05.19	05.19
Removed HIM line of business; updated preferred redirections based on SDC recommendation and prior clinical guidance: for PsA, changed redirection from adalimumab and etanercept to a trial of 3 of 5 (Enbrel, Simponi/Simponi Aria, Taltz, Otezla, Xeljanz/Xeljanz XR); for PsO, removed redirection to adalimumab and added redirection to Taltz; for AS, removed redirection to adalimumab and added redirection to 2 of 3 (Enbrel, Cimzia, Taltz).	12.13.19	
2Q 2020 annual review: no significant changes; for AS, added requirement of inadequate response to a $\geq 3$ consecutive month trial of 150 mg every 4 weeks for increased maintenance dosing of 300 mg every 4 weeks per updated PI; references reviewed and updated.	03.02.20	05.20
Criteria added for new FDA indication: nr-axSpA; required redirection to only Cimzia and Taltz due to off-label status of Enbrel for nr-axSpA while maintaining redirection to Cimzia, Enbrel, and Taltz when the diagnosis is AS; references reviewed and updated.	06.25.20	11.20
2Q 2021 annual review: added additional criteria related to diagnosis of moderate-to-severe PsO per 2019 AAD/NPF guidelines specifying at least 3% BSA involvement or involvement of areas that severely impact daily function; added combination of bDMARDs under Section III; references reviewed and updated.	02.23.21	05.21
RT4: updated PsO age requirement from $\geq 18$ years to $\geq 6$ years per FDA pediatric expansion; added new 75 mg/0.5 mL prefilled syringe for pediatric patients.	06.04.21	
Per SDC and prior clinical guidance, for AS, revised redirection requirement from two among the preferred to all of the preferred; for PsA removed Simponi as a redirect option and modified to require a trial of all; for Xeljanz redirection requirements added bypass for members with cardiovascular risk and qualified redirection to apply only for member that has not responded or is intolerant to one or	08.25.21	11.21

Reviews, Revisions, and Approvals	Date	P&T Approval Date
more TNF blockers; added Legacy WellCare line of business to policy (WCG.CP.PHAR.261 to be retired).		
2Q 2022 annual review: for AS, added redirection to Xeljanz if failed prior TNF blocker per August SDC and updated FDA labeling; RT4: applied FDA-approved pediatric use extension down to 2 years of age for active PsA; for PsA, modified redirection to apply for age 18 or older; added newly approved indication for active ERA; for PsO, allowed phototherapy as alternative to systemic conventional DMARD if contraindicated or clinically significant adverse effects are experienced; removed separate legacy wellcare approval durations; reiterated requirement against combination use with a bDMARD or JAKi from Section III to Sections I and II; references reviewed and updated.	02.18.22	05.22
Template changes applied to other diagnoses/indications and continued therapy section.	10.13.22	
2Q 2023 annual review: updated off-label dosing in Appendix B; for AS and PsA, added TNFi criteria to allow bypass if member has had history of failure of two TNF blockers; references reviewed and updated.	02.10.23	05.23
RT4: added new dosage forms (UnoReady Pen and 300 mg/2 mL dose of pre-filled syringe) to policy.	05.25.23	
Per July SDC: for AS, removed criteria requiring use of Enbrel and Cimzia; for PsA and ERA, removed criteria requiring use of Enbrel; for AS, PsO, PsA, added criteria requiring use of one adalimumab product and stating Yusimry, Hadlima, unbranded adalimumab-fkjp, and unbranded adalimumab-adaz as preferred; for nr-axSpA, removed redirection to Cimzia; updated Appendix B with relevant therapeutic alternatives.	07.25.23	
RT4: added new dosage form single-dose vial 125 mg/ 5 mL for intravenous infusion; added IV specific dosing for AS, nr-axSpA and PsA; added Tofidence to section III.B.	10.30.23	
Per December SDC, added adalimumab-adbm to listed examples of preferred adalimumab products. RT4: added newly approved HS indication to criteria; added Wezlana to section III.B; updated HCPCS code description for J3590.	12.06.23	02.24
Added new HCPCS code [C9166] and removed HCPCS codes [C9399, J3590].	02.19.24	

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional

organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.



©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.